All Digital only Industry Symposia
Saturday, 10 July 2021
Digital Company Sponsored Symposia (DCSS) / Digital Satellite Symposia (DSAT) / Digital Company Sponsored Mini Symposia (DCSMS)
All Digital only Symposia will be made available on the EAACI Hybrid Congress 2021 digital platform.
DCSMS 1-1
12:00 – 12:30
Sanofi Genzyme and Regeneron: Type 2 Inflammation: What every clinician should know
How can we most effectively translate the science of Type 2 inflammation into clinically relevant insights that inform management of severe asthma?
Speakers: Hans in ‘t Veen, The Netherlands; Jasper Kappen, The Netherlands
DSAT 1-1
12:45 – 13:45
Novartis: IgE in asthma and nasal polyposis: your questions answered
Chair: Marcus Maurer, Germany
Welcome and introduction
Speaker: Marcus Maurer, Germany
Panel discussion:
Why is it important to consider comorbidities when treating patients with asthma?
Anti-IgE therapy is well established in severe allergic asthma, what do we know
about it in nasal polyposis?
How should physicians choose between the biological agents available?
How important is a multi-disciplinary approach for patients?
Speakers: Enrico Heffler, Italy; Philippe Gevaert, Belgium
DSAT 1-2
12:45 – 13:45
Takeda: Looking ahead to the future: Advances in HAE diagnostics
Chair: Marcus Maurer, Germany
Welcome and introduction to diagnosing HAE
Speaker: Marcus Maurer, Germany
Current tools for diagnosing HAE
Speaker: Henriette Farkas, Hungary
The future of HAE diagnosis
Speaker: Jonathan Bernstein, USA
Live question and answer session
Speakers: Marcus Maurer, Germany; Henriette Farkas, Hungary; Jonathan Bernstein, USA
Closing remarks
Speaker: Marcus Maurer, Germany
DCSMS 1-2
14:00 – 14:30
Sanofi Genzyme and Regeneron: CRSwNP, a Type 2 Inflammatory disease: Changing treatment paradigm
CRSwNP as a Type 2 Inflammatory disease: Then and now
Speaker: Claus Bachert, Belgium
Managing CRSwNP: Critical insights into the use of biologics
Speaker: Joaquim Mullol, Spain
DCSMS 1-3
14:45 – 15:15
Sanofi Genzyme and Regeneron: Breaking new ground: A closer look at Type 2 Inflammation in pediatric asthma
Revealing the burden of severe asthma in pediatric populations
Speaker: Leonard Bacharier, USA
Unmasking Type 2 Inflammation in pediatric asthma
Speaker: Nikolaos Papadopoulos, UK
Staying on target: Novel approaches to managing pediatric severe asthma
Speaker: Leonard Bacharier, USA
DCSMS 1-4
15:30 – 16:00
Sanofi Genzyme and Regeneron: Exploring the Complexity of Chronic Spontaneous Urticaria
Chronic Spontaneous Urticaria (CSU): unpredictable, chronic and burdensome
Speaker: Jonathan Bernstein, USA
CSU has a complex pathophysiology involving autoimmunity, autoallergy, and type 2 inflammation
Speaker: Marcus Maurer, Germany
Current clinical challenges in CSU
Speakers: Jonathan Bernstein, USA; Marcus Maurer, Germany
DSAT 1-3
16:15 – 17:15
FAES FARMA and Menarini Group: Clinical Cases in discussion: 3 patients, 3 experts & 1 solution
Chairs: Pablo Rodriguez, Spain; Fulvio Braido, Italy; Torsten Zuberbier, Germany
Urticaria and Rhinitis in children
Speaker: Pablo Rodriguez, Spain
United Airway Disease, Allergic Rhinitis and its Impact on Asthma
Speaker: Fulvio Braido, Italy
Urticaria
Speaker: Torsten Zuberbier, Germany
DSAT 1-4
18:00 – 19:00
OM Pharma: Strengthening the immune system to reduce asthma risk: paving the way to the future?
Chair: Jonathan Grigg, UK
Welcome & Introduction
Speaker: Jonathan Grigg, UK
Highlights on the concept of innate immune training
Speaker: Alberto Mantovani, Italy
Could therapy with bacterial products prevent asthma?
Speaker: Jonathan Grigg, UK
How to improve control of infectious asthma exacerbations in adults: state-of-art and future perspectives
Speaker: Gerdien Tramper, The Netherlands
Roundtable discussion
Speakers: Jonathan Grigg, United Kingdom, Alberto Mantovani, Italy; Gerdien Tramper, The Netherlands
Take-home messages and closing remarks
Speaker: Jonathan Grigg, UK
DCSS 1-1
18:00 – 19:30
Allergy Therapeutics: Pioneering a new age – fighting allergic disease on all fronts!
Chair: Ignacio Dávila, Spain
MCT – an evidence-based adjuvant in allergen immunotherapy
Speaker: Ralph Mösges, Germany
Insect Venom Allergy – exploring the current landscape
Speaker: Thilo Jakob, Germany
Beta-lactoglobulin – from farm stable dust to a lozenge inducing immune resilience in allergic diseases
Speaker: Erika Jensen-Jarolim, Austria
DCSS 1-2
18:00 – 19:30
Aimmune Therapeutics: The treatment of peanut allergy with PALFORZIA®, from clinical development to practical experience
Chair: Antonella Muraro, Italy
Introduction to peanut allergy and PALFORZIA
Speaker: Antonella Muraro, Italy
PALFORZIA: data review
Speaker: Katharina Blümchen, Germany
PALFORZIA: interpreting the data
Speaker: George du Toit, UK
PALFORZIA: learning from US practical experience
Speaker: Joel Hartman, USA
DCSS 1-3
18:00 – 19:30
CSL Behring: The Evolving Evidence for the Long-Term, Prophylactic Treatment of Hereditary Angioedema Patients with Subcutaneous C1-INH
Chair: Marcus Maurer, Germany
Welcome and Introductions
Speaker: Marcus Maurer, Germany
Learnings from the HAE Guidelines
Speaker: Markus Magerl, Germany
Examining the Evidence Regarding C1-INH (SC) in All Populations, with an Emphasis on Special Populations
Speaker: Donald Levy, USA
Using Clinical and Real-World Experience to Inform Treatment Decisions
Speaker: Stefan Cimbollek, Spain
Q&A Session, Summary and Close
Speaker: Marcus Maurer, Germany
Sunday, 11 July 2021
DSAT 2-1
08:00 – 09:00
Abbott Laboratories: Expansion of Hydrolysed Rice Formula for Infants with Cow’s Milk Allergy: Considerations for Clinical Practice
Chair: Alessandro Fiocchi, Italy; Rosan Meyer, UK; Christophe Dupont, France
Welcome and introductions
Speaker: Alessandro Fiocchi, Italy
Overview of CMA and introducing a hydrolysed rice formula
Speaker: Alessandro Fiocchi, Italy
Practical experience using hydrolysed rice formula from a gastroenterologist’s perspective
Speaker: Christophe Dupont, France
The dietetic perspective of hydrolysed rice protein formulas
Speaker: Rosan Meyer, UK
Q&A
Speakers: Alessandro Fiocchi, Italy; Rosan Meyer, UK; Christophe Dupont, France
DSAT 2-3
10:00 – 11:00
BioCryst: Rethinking hereditary angioedema: What role can the first oral plasma kallikrein inhibitor play?
Chair: Marcin Stobiecki, Poland
Reflection on hereditary angioedema (HAE): Progress and perspectives
Speaker: Marcin Stobiecki, Poland
A new view: What is the role of an oral plasma kallikrein inhibitor?
Speaker: Emel Aygören-Pürsün, Germany
Changing times: How can we optimise patient transition between therapies?
Speaker: Marcin Stobieck, Poland
From clinical data to real-world evidence: Does the reality match the theory?
Speaker: Delphine Gobert, France
Applied thinking: What can we learn from the evidence?
Speaker: Sorena Kiani, UK
Looking ahead in HAE: What should our vision be?
Speaker: Marcin Stobiecki, Poland
DCSMS 2-2
12:00 – 12:30
Sanofi Genzyme and Regeneron: Targeting Type 2 mechanisms in patients with atopic dermatitis and comorbid Type 2 Inflammatory disease: A case-based reflection
Connecting Type 2 Inflammation to clinical characteristics of disease
Speaker: Mark Boguniewciz, United States
DSAT 2-4
12:45 – 13:45
Novartis: IgE-mediated food allergy: need for a revolution
Chair: Marcus Maurer, Germany
Panel discussion:
Why do we need to be concerned about food allergy?
What is the role of IgE in food allergy?
What have we learned about epitope-specific IgE from the LEAP study?
What are the advances in food allergy diagnostics?
Do current treatment options meet the needs of people with food allergy?
What more can we do together to improve food allergy care?
Speakers: George du Toit, UK; Hugh Sampson, USA; Alexandra Santos, UK
DSAT 2-5
12:45 – 13:45
Takeda: Efficacy and quality of life in HAE: The lanadelumab experience
Chair: Waserman Susan, Canada
Welcome and introductions
Speaker: Susan Waserman, Canada
Living with HAE
Speaker: Patient ambassador (name confidential), UK
The true burden of HAE
Speaker: Susan Waserman, Canada
An overview of the efficacy, safety and QoL data from the HELP and HELP OLE studies
Speaker: Sinisa Savic, UK
Efficacy, safety and QoL in a real-world setting: Experience from France
Speaker: Laurence Bouillet, France
Closing remarks
Speaker: Susan Waserman, Canada
DCSMS 2-3
14.00 -14.30
Revenio Research Oy: Re-thinking lung function testing in young children
Chair: Ville-Pekka Seppä, Finland
Pediatric asthma
Speaker: Mika Mäkelä, Finland
DCSMS 2-4
14:45 – 15:15
BluePrint Medicines: Systemic Mastocytosis – An Allergist/Immunologist Perspective
Chair: Vito Sabato, Belgium
Systemic Mastocytosis – An Allergist/Immunologist Perspective
Speaker: Vito Sabato, Belgium
DCSMS 2-5
15:30 – 16:00
Sanofi Genzyme and Regeneron: Championing change: Is elimination of oral corticosteroid use in asthma achievable today?
OCS in patients with uncontrolled asthma: An unaddressed challenge
Speaker: Ian Pavord, UK
Corticosteroid Overload: The Compounding Burden in Patients
Speaker: Tanya Laidlaw, USA
Current Strategies for Reducing Corticosteroid Use: How Far Have We Come?
Speakers: Ian Pavord, United Kingdom; Tanya Laidlaw, USA
Changing the Script: Improving Asthma Management in OCS-Dependent Patients
Speakers: Ian Pavord, United Kingdom; Tanya Laidlaw, USA
DSAT 2-7
18:15 – 19:15
Purina Institute: A transformational approach to managing allergies to cats
Chair: Antonella Muraro, Italy
A transformational approach to managing allergies to cats – Part I
Speaker: Antonella Muraro, Italy
A transformational approach to managing allergies to cats – Part II
Speaker: Ebenezer Satyaraj, USA
Continuation
Speaker: Antonella Muraro, Italy
DSAT 2-13
19:15 – 20:15
Uriach: Mind the PAF: a new route to managing chronic urticaria and allergic diseases?
Chair: Frank Siebenhaar, Germany
Welcome address
Speaker: Frank Siebenhaar, Germany
Introduction to PAF and PAF targeting treatments
Speaker: Frank Siebenhaar, Germany
Targeting PAF in allergic rhinitis: a responder analysis to rupatadine
Speaker: Joaquim Mullol, Spain
Targeting PAF in chronic spontaneous urticaria: a success story
Speaker: Ana M. Giménez-Arnau, Spain
Panel discussion
Speakers: Frank Siebenhaar, Germany; Joaquim Mullol, Spain; Ana M. Giménez-Arnau, Spain
Closing statement
Speaker: Frank Siebenhaar, Germany
Monday, 12 July 2021
DCSMS 3-1
12:15 – 12:45
Sanofi Genzyme and Regeneron: Type 2 Asthma and FeNO: The Clinician’s Tool in Precision Treatment
No single biomarker can capture the full spectrum of Type 2 inflammation in asthma.
Clinical utility of FeNO, among other biomarkers, in the management of patients with severe asthma. Illustrated through rea
Speakers. Anh Tuan Dinh-Xuan, France; Stephanie Korn, Germany
DSAT 3-1
13:00 – 14:00
Novartis: Complete control of chronic spontaneous urticaria – mission (im)possible?
Chair: Marcus Maurer, Germany
Welcome & Introduction
Speaker: Marcus Maurer, Germany
Why do our patients fail to reach complete control?
Speaker: Zenon Brzoza, Poland
How can targeting IgE contribute to complete control?
Speaker: Marcus Maurer, Germany
Questions and answers
Speakers: Marcus Maurer, Germany; Zenon Brzoza, Poland
DSAT 3-2
13:00 – 14:00
MSD: Chronic Cough & Refractory Chronic Cough: Preparing for the Future
Chair: Joaquin Sastre, Spain
Opening Remarks
Speaker: Joaquin Sastre, Spain
From Cough in Health to Cough in Disease; the Multiple Pathways
Speaker: Brendan Canning, USA
Facing the Challenge: Diagnosing and Managing Chronic Cough
Speaker: Woo-Jung Song, Korea
Q&A and Panel discussion
Speakers: Joaquin Sastre, Spain; Brendan Canning, USA; Woo-Jung Song, Korea